_id
6918473b3c536f8df2317825
Ticker
ZLAB
Name
Zai Lab Ltd
Exchange
NASDAQ
Address
Building B, Pudong, China, 201203
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.zailaboratory.com
Description
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.
Last Close
17.82
Volume
875883
Current Price
17.77
Change
-0.28058361391695125
Last Updated
2025-12-05T14:18:10.599Z
Image
https://logo.clearbit.com/www.zailaboratory.com
Ipo Date
2017-09-20T00:00:00.000Z
Market Cap
2206345472
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.98775
Sentiment Sources
4
Rating
4.5
Target Price
49.4882
Strong Buy
7
Buy
4
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
116095000
Cost Of Revenue
46883000
Gross Profit
69212000
Operating Expenses
118034000
Operating Income
-48822000
Interest Expense
1400000
Pretax Income
-35963000
Net Income
-35963000
Eps
-0.3263214908838862
Dividends Per Share
-
Shares Outstanding
110593760
Income Tax Expense
-
EBITDA
-30662000
Operating Margin
-42.053490675739695
Total Other Income Expense Net
12859000
Cash
717155000
Short Term Investments
0
Receivables
105005000
Inventories
67135000
Total Current Assets
1032948000
Property Plant Equipment
64619000
Total Assets
1158940000
Payables
99706000
Short Term Debt
208522000
Long Term Debt
-
Total Liabilities
398995000
Equity
759945000
Depreciation
3901000
Change In Working Capital
-11764000
Cash From Operations
-32044000
Capital Expenditures
4086000
Cash From Investing
-4049000
Cash From Financing
20793000
Net Change In Cash
-15114000
PE
-
PB
2.577006431202258
ROE
-4.732316154458546
ROA
-3.1030942067751566
FCF
-36130000
Fcf Percent
-0.3112106464533356
Piotroski FScore
1
Health Score
31
Deep Value Investing Score
3.5
Defensive Investing Score
6.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.3
Garp Investing Score
2.5
Growth Investing Score
1.5
Momentum Investing Score
2
Net Net Investing Score
3
Quality Investing Score
2
Value Investing Score
3.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
116095000
Quarters > 0 > income Statement > cost Of Revenue
46883000
Quarters > 0 > income Statement > gross Profit
69212000
Quarters > 0 > income Statement > operating Expenses
118034000
Quarters > 0 > income Statement > operating Income
-48822000
Quarters > 0 > income Statement > interest Expense
1400000
Quarters > 0 > income Statement > pretax Income
-35963000
Quarters > 0 > income Statement > net Income
-35963000
Quarters > 0 > income Statement > eps
-0.3263214908838862
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
110207268
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-30662000
Quarters > 0 > income Statement > operating Margin
-42.053490675739695
Quarters > 0 > income Statement > total Other Income Expense Net
12859000
Quarters > 0 > balance Sheet > cash
717155000
Quarters > 0 > balance Sheet > short Term Investments
0
Quarters > 0 > balance Sheet > receivables
105005000
Quarters > 0 > balance Sheet > inventories
67135000
Quarters > 0 > balance Sheet > total Current Assets
1032948000
Quarters > 0 > balance Sheet > property Plant Equipment
64619000
Quarters > 0 > balance Sheet > total Assets
1158940000
Quarters > 0 > balance Sheet > payables
99706000
Quarters > 0 > balance Sheet > short Term Debt
208522000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
398995000
Quarters > 0 > balance Sheet > equity
759945000
Quarters > 0 > cash Flow > net Income
-35963000
Quarters > 0 > cash Flow > depreciation
3901000
Quarters > 0 > cash Flow > change In Working Capital
-11764000
Quarters > 0 > cash Flow > cash From Operations
-32044000
Quarters > 0 > cash Flow > capital Expenditures
4086000
Quarters > 0 > cash Flow > cash From Investing
-4049000
Quarters > 0 > cash Flow > cash From Financing
20793000
Quarters > 0 > cash Flow > net Change In Cash
-15114000
Quarters > 0 > ratios > PE
-0.3263214908838862
Quarters > 0 > ratios > PB
2.577006431202258
Quarters > 0 > ratios > ROE
-4.732316154458546
Quarters > 0 > ratios > ROA
-3.1030942067751566
Quarters > 0 > ratios > FCF
-36130000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-0.3112106464533356
Quarters > 0 > health Score
31
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
109977000
Quarters > 1 > income Statement > cost Of Revenue
43220000
Quarters > 1 > income Statement > gross Profit
66757000
Quarters > 1 > income Statement > operating Expenses
121652000
Quarters > 1 > income Statement > operating Income
-54895000
Quarters > 1 > income Statement > interest Expense
1262000
Quarters > 1 > income Statement > pretax Income
-40727000
Quarters > 1 > income Statement > net Income
-40727000
Quarters > 1 > income Statement > eps
-0.3729807598085231
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
109193300
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-35730000
Quarters > 1 > income Statement > operating Margin
-49.91498222355584
Quarters > 1 > income Statement > total Other Income Expense Net
14168000
Quarters > 1 > balance Sheet > cash
732159000
Quarters > 1 > balance Sheet > short Term Investments
0
Quarters > 1 > balance Sheet > receivables
99342000
Quarters > 1 > balance Sheet > inventories
61700000
Quarters > 1 > balance Sheet > total Current Assets
1034062000
Quarters > 1 > balance Sheet > property Plant Equipment
66947000
Quarters > 1 > balance Sheet > total Assets
1164101000
Quarters > 1 > balance Sheet > payables
107357000
Quarters > 1 > balance Sheet > short Term Debt
180093000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
372366000
Quarters > 1 > balance Sheet > equity
791735000
Quarters > 1 > cash Flow > net Income
-40727000
Quarters > 1 > cash Flow > depreciation
3735000
Quarters > 1 > cash Flow > change In Working Capital
-10335000
Quarters > 1 > cash Flow > cash From Operations
-31024000
Quarters > 1 > cash Flow > capital Expenditures
552000
Quarters > 1 > cash Flow > cash From Investing
-2922000
Quarters > 1 > cash Flow > cash From Financing
8849000
Quarters > 1 > cash Flow > net Change In Cash
-24992000
Quarters > 1 > ratios > PE
-0.3729807598085231
Quarters > 1 > ratios > PB
2.4507757532507717
Quarters > 1 > ratios > ROE
-5.1440191478209245
Quarters > 1 > ratios > ROA
-3.498579590602534
Quarters > 1 > ratios > FCF
-31576000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-0.28711457850277783
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
106487000
Quarters > 2 > income Statement > cost Of Revenue
38647000
Quarters > 2 > income Statement > gross Profit
67840000
Quarters > 2 > income Statement > operating Expenses
124151000
Quarters > 2 > income Statement > operating Income
-56311000
Quarters > 2 > income Statement > interest Expense
1187000
Quarters > 2 > income Statement > pretax Income
-48438000
Quarters > 2 > income Statement > net Income
-48438000
Quarters > 2 > income Statement > eps
-0.4481555841344152
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
108083000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-43793000
Quarters > 2 > income Statement > operating Margin
-52.88063331674289
Quarters > 2 > income Statement > total Other Income Expense Net
7873000
Quarters > 2 > balance Sheet > cash
757263000
Quarters > 2 > balance Sheet > short Term Investments
0
Quarters > 2 > balance Sheet > receivables
87673000
Quarters > 2 > balance Sheet > inventories
53054000
Quarters > 2 > balance Sheet > total Current Assets
1041868000
Quarters > 2 > balance Sheet > property Plant Equipment
68735000
Quarters > 2 > balance Sheet > total Assets
1173330000
Quarters > 2 > balance Sheet > payables
103017000
Quarters > 2 > balance Sheet > short Term Debt
179979000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
362577000
Quarters > 2 > balance Sheet > equity
810753000
Quarters > 2 > cash Flow > net Income
-48438000
Quarters > 2 > cash Flow > depreciation
3458000
Quarters > 2 > cash Flow > change In Working Capital
-34939000
Quarters > 2 > cash Flow > cash From Operations
-61699000
Quarters > 2 > cash Flow > capital Expenditures
3867000
Quarters > 2 > cash Flow > cash From Investing
326133000
Quarters > 2 > cash Flow > cash From Financing
43141000
Quarters > 2 > cash Flow > net Change In Cash
307595000
Quarters > 2 > ratios > PE
-0.4481555841344152
Quarters > 2 > ratios > PB
2.368951961941553
Quarters > 2 > ratios > ROE
-5.974445977998231
Quarters > 2 > ratios > ROA
-4.128250364347625
Quarters > 2 > ratios > FCF
-65566000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-0.6157183505967865
Quarters > 2 > health Score
34
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
109070000
Quarters > 3 > income Statement > cost Of Revenue
42091000
Quarters > 3 > income Statement > gross Profit
66979000
Quarters > 3 > income Statement > operating Expenses
134870000
Quarters > 3 > income Statement > operating Income
-67891000
Quarters > 3 > income Statement > interest Expense
904000
Quarters > 3 > income Statement > pretax Income
-81684000
Quarters > 3 > income Statement > net Income
-81684000
Quarters > 3 > income Statement > eps
-0.8027753754225961
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
101752000
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-75433000
Quarters > 3 > income Statement > operating Margin
-62.24534702484643
Quarters > 3 > income Statement > total Other Income Expense Net
-13793000
Quarters > 3 > balance Sheet > cash
449667000
Quarters > 3 > balance Sheet > short Term Investments
330000000
Quarters > 3 > balance Sheet > receivables
89411000
Quarters > 3 > balance Sheet > inventories
39875000
Quarters > 3 > balance Sheet > total Current Assets
1050480000
Quarters > 3 > balance Sheet > property Plant Equipment
69475000
Quarters > 3 > balance Sheet > total Assets
1185753000
Quarters > 3 > balance Sheet > payables
100906000
Quarters > 3 > balance Sheet > short Term Debt
139759000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
344855000
Quarters > 3 > balance Sheet > equity
840898000
Quarters > 3 > cash Flow > net Income
-81684000
Quarters > 3 > cash Flow > depreciation
3032000
Quarters > 3 > cash Flow > change In Working Capital
-19138000
Quarters > 3 > cash Flow > cash From Operations
-55769000
Quarters > 3 > cash Flow > capital Expenditures
17754000
Quarters > 3 > cash Flow > cash From Investing
-347754000
Quarters > 3 > cash Flow > cash From Financing
237812000
Quarters > 3 > cash Flow > net Change In Cash
-166423000
Quarters > 3 > ratios > PE
-0.8027753754225961
Quarters > 3 > ratios > PB
2.1502406237141725
Quarters > 3 > ratios > ROE
-9.713901091452232
Quarters > 3 > ratios > ROA
-6.888787125143263
Quarters > 3 > ratios > FCF
-73523000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-0.6740900339231686
Quarters > 3 > health Score
35
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
398988000
Annuals > 0 > income Statement > cost Of Revenue
147860000
Annuals > 0 > income Statement > gross Profit
251128000
Annuals > 0 > income Statement > operating Expenses
533245000
Annuals > 0 > income Statement > operating Income
-282117000
Annuals > 0 > income Statement > interest Expense
2254000
Annuals > 0 > income Statement > pretax Income
-257103000
Annuals > 0 > income Statement > net Income
-257103000
Annuals > 0 > income Statement > eps
-2.598364797671504
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
98948000
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-234574000
Annuals > 0 > income Statement > operating Margin
-70.70814159824356
Annuals > 0 > income Statement > total Other Income Expense Net
25014000
Annuals > 0 > balance Sheet > cash
449667000
Annuals > 0 > balance Sheet > short Term Investments
330000000
Annuals > 0 > balance Sheet > receivables
89411000
Annuals > 0 > balance Sheet > inventories
39875000
Annuals > 0 > balance Sheet > total Current Assets
1050480000
Annuals > 0 > balance Sheet > property Plant Equipment
69475000
Annuals > 0 > balance Sheet > total Assets
1185753000
Annuals > 0 > balance Sheet > payables
100906000
Annuals > 0 > balance Sheet > short Term Debt
139759000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
344855000
Annuals > 0 > balance Sheet > equity
840898000
Annuals > 0 > cash Flow > net Income
-257103000
Annuals > 0 > cash Flow > depreciation
11856000
Annuals > 0 > cash Flow > change In Working Capital
-68390000
Annuals > 0 > cash Flow > cash From Operations
-214869000
Annuals > 0 > cash Flow > capital Expenditures
61522000
Annuals > 0 > cash Flow > cash From Investing
-375193000
Annuals > 0 > cash Flow > cash From Financing
349889000
Annuals > 0 > cash Flow > net Change In Cash
-240483000
Annuals > 0 > ratios > PE
-2.598364797671504
Annuals > 0 > ratios > PB
2.3475054049361512
Annuals > 0 > ratios > ROE
-30.574814067817975
Annuals > 0 > ratios > ROA
-21.682677589683518
Annuals > 0 > ratios > FCF
-276391000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-0.692730107171143
Annuals > 0 > health Score
34
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
266719000
Annuals > 1 > income Statement > cost Of Revenue
95816000
Annuals > 1 > income Statement > gross Profit
170903000
Annuals > 1 > income Statement > operating Expenses
537476000
Annuals > 1 > income Statement > operating Income
-366573000
Annuals > 1 > income Statement > interest Expense
14582000
Annuals > 1 > income Statement > pretax Income
-334620000
Annuals > 1 > income Statement > net Income
-334620000
Annuals > 1 > income Statement > eps
-34.625625301313406
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
9663941
Annuals > 1 > income Statement > income Tax Expense
38929000
Annuals > 1 > income Statement > EBITDA
-365111000
Annuals > 1 > income Statement > operating Margin
-137.43790281157322
Annuals > 1 > income Statement > total Other Income Expense Net
31953000
Annuals > 1 > balance Sheet > cash
790151000
Annuals > 1 > balance Sheet > short Term Investments
16300000
Annuals > 1 > balance Sheet > receivables
65333000
Annuals > 1 > balance Sheet > inventories
44827000
Annuals > 1 > balance Sheet > total Current Assets
939606000
Annuals > 1 > balance Sheet > property Plant Equipment
68689000
Annuals > 1 > balance Sheet > total Assets
1036295000
Annuals > 1 > balance Sheet > payables
112991000
Annuals > 1 > balance Sheet > short Term Debt
7104000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
240177000
Annuals > 1 > balance Sheet > equity
796118000
Annuals > 1 > cash Flow > net Income
-334620000
Annuals > 1 > cash Flow > depreciation
9029000
Annuals > 1 > cash Flow > change In Working Capital
39606000
Annuals > 1 > cash Flow > cash From Operations
-198178000
Annuals > 1 > cash Flow > capital Expenditures
8491000
Annuals > 1 > cash Flow > cash From Investing
-10776000
Annuals > 1 > cash Flow > cash From Financing
-6433000
Annuals > 1 > cash Flow > net Change In Cash
-218009000
Annuals > 1 > ratios > PE
-34.625625301313406
Annuals > 1 > ratios > PB
0.2421696569478394
Annuals > 1 > ratios > ROE
-42.031457648238074
Annuals > 1 > ratios > ROA
-32.29003324342972
Annuals > 1 > ratios > FCF
-206669000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-0.7748566843756912
Annuals > 1 > health Score
33
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
215040000
Annuals > 2 > income Statement > cost Of Revenue
74018000
Annuals > 2 > income Statement > gross Profit
141022000
Annuals > 2 > income Statement > operating Expenses
545379000
Annuals > 2 > income Statement > operating Income
-404357000
Annuals > 2 > income Statement > interest Expense
14582000
Annuals > 2 > income Statement > pretax Income
-443286000
Annuals > 2 > income Statement > net Income
-443286000
Annuals > 2 > income Statement > eps
-46.268784305399905
Annuals > 2 > income Statement > dividends Per Share
16055000
Annuals > 2 > income Statement > shares Outstanding
9580671
Annuals > 2 > income Statement > income Tax Expense
221000
Annuals > 2 > income Statement > EBITDA
-434838000
Annuals > 2 > income Statement > operating Margin
-188.03803943452382
Annuals > 2 > income Statement > total Other Income Expense Net
-38929000
Annuals > 2 > balance Sheet > cash
1008470000
Annuals > 2 > balance Sheet > short Term Investments
0
Annuals > 2 > balance Sheet > receivables
48571000
Annuals > 2 > balance Sheet > inventories
31621000
Annuals > 2 > balance Sheet > total Current Assets
1124336000
Annuals > 2 > balance Sheet > property Plant Equipment
78771000
Annuals > 2 > balance Sheet > total Assets
1220140000
Annuals > 2 > balance Sheet > payables
65974000
Annuals > 2 > balance Sheet > short Term Debt
7050000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
174545000
Annuals > 2 > balance Sheet > equity
1045595000
Annuals > 2 > cash Flow > net Income
-443286000
Annuals > 2 > cash Flow > depreciation
8227000
Annuals > 2 > cash Flow > change In Working Capital
-66247000
Annuals > 2 > cash Flow > cash From Operations
-367642000
Annuals > 2 > cash Flow > capital Expenditures
24984000
Annuals > 2 > cash Flow > cash From Investing
420016000
Annuals > 2 > cash Flow > cash From Financing
-1730000
Annuals > 2 > cash Flow > net Change In Cash
44370000
Annuals > 2 > ratios > PE
-46.268784305399905
Annuals > 2 > ratios > PB
0.18279963700094204
Annuals > 2 > ratios > ROE
-42.395573812040034
Annuals > 2 > ratios > ROA
-36.3307489304506
Annuals > 2 > ratios > FCF
-392626000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-1.8258277529761904
Annuals > 2 > health Score
33
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
144312000
Annuals > 3 > income Statement > cost Of Revenue
52239000
Annuals > 3 > income Statement > gross Profit
92073000
Annuals > 3 > income Statement > operating Expenses
792137000
Annuals > 3 > income Statement > operating Income
-700064000
Annuals > 3 > income Statement > interest Expense
3350000
Annuals > 3 > income Statement > pretax Income
-703414000
Annuals > 3 > income Statement > net Income
-704471000
Annuals > 3 > income Statement > eps
-75.75599693350328
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
9299211
Annuals > 3 > income Statement > income Tax Expense
1057000
Annuals > 3 > income Statement > EBITDA
-689464000
Annuals > 3 > income Statement > operating Margin
-485.1044958146239
Annuals > 3 > income Statement > total Other Income Expense Net
-3350000
Annuals > 3 > balance Sheet > cash
964100000
Annuals > 3 > balance Sheet > short Term Investments
445000000
Annuals > 3 > balance Sheet > receivables
54809000
Annuals > 3 > balance Sheet > inventories
18951000
Annuals > 3 > balance Sheet > total Current Assets
1500881000
Annuals > 3 > balance Sheet > property Plant Equipment
58280000
Annuals > 3 > balance Sheet > total Assets
1609956000
Annuals > 3 > balance Sheet > payables
126163000
Annuals > 3 > balance Sheet > short Term Debt
5927000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
230000000
Annuals > 3 > balance Sheet > equity
1379956000
Annuals > 3 > cash Flow > net Income
-704471000
Annuals > 3 > cash Flow > depreciation
6487000
Annuals > 3 > cash Flow > change In Working Capital
23110000
Annuals > 3 > cash Flow > cash From Operations
-549231000
Annuals > 3 > cash Flow > capital Expenditures
18948000
Annuals > 3 > cash Flow > cash From Investing
249957000
Annuals > 3 > cash Flow > cash From Financing
820202000
Annuals > 3 > cash Flow > net Change In Cash
522044000
Annuals > 3 > ratios > PE
-75.75599693350328
Annuals > 3 > ratios > PB
0.1344385324242222
Annuals > 3 > ratios > ROE
-51.05025087756421
Annuals > 3 > ratios > ROA
-43.7571585807314
Annuals > 3 > ratios > FCF
-568179000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-3.93715699318144
Annuals > 3 > health Score
33
Valuation > metrics > PE
-0.3263214908838862
Valuation > metrics > PB
2.577006431202258
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-4.732316154458546
Profitability > metrics > ROA
-3.4815886182073057
Profitability > metrics > Net Margin
-0.30977216934407165
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.5250314167472646
Risk > metrics > Interest Coverage
-34.87285714285714
Risk > final Score
-91
Risk > verdict
High
Liquidity > metrics > Current Ratio
3.3512464798785313
Liquidity > metrics > Quick Ratio
3.1334369362939123
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-114
Prev Risks > 1
-130
Prev Risks > 2
-240
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-13T01:39:23.186Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-03
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
0
Earnings History > 0 > eps Estimate
-0.0882
Earnings History > 0 > eps Difference
0.0882
Earnings History > 0 > surprise Percent
100
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-11-06
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.33
Earnings History > 1 > eps Estimate
-0.2453
Earnings History > 1 > eps Difference
-0.0847
Earnings History > 1 > surprise Percent
-34.5291
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-08-07
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.04
Earnings History > 2 > eps Estimate
-0.41
Earnings History > 2 > eps Difference
0.37
Earnings History > 2 > surprise Percent
90.2439
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-05-06
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
AfterMarket
Earnings History > 3 > currency
USD
Earnings History > 3 > eps Actual
-0.45
Earnings History > 3 > eps Estimate
-0.5475
Earnings History > 3 > eps Difference
0.0975
Earnings History > 3 > surprise Percent
17.8082
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-02-25
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
BeforeMarket
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-0.8
Earnings History > 4 > eps Estimate
-0.6333
Earnings History > 4 > eps Difference
-0.1667
Earnings History > 4 > surprise Percent
-26.3224
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-11-12
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
BeforeMarket
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.42
Earnings History > 5 > eps Estimate
-0.78
Earnings History > 5 > eps Difference
0.36
Earnings History > 5 > surprise Percent
46.1538
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-08-06
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
AfterMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.8
Earnings History > 6 > eps Estimate
-0.71
Earnings History > 6 > eps Difference
-0.09
Earnings History > 6 > surprise Percent
-12.6761
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-05-08
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
AfterMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.5
Earnings History > 7 > eps Estimate
-0.92
Earnings History > 7 > eps Difference
0.42
Earnings History > 7 > surprise Percent
45.6522
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2024-02-27
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
AfterMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-1
Earnings History > 8 > eps Estimate
-0.86
Earnings History > 8 > eps Difference
-0.14
Earnings History > 8 > surprise Percent
-16.2791
Earnings History > 9 > period
2023-09-30
Earnings History > 9 > report Date
2023-11-07
Earnings History > 9 > date
2023-09-30
Earnings History > 9 > before After Market
AfterMarket
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
-0.71
Earnings History > 9 > eps Estimate
-1.04
Earnings History > 9 > eps Difference
0.33
Earnings History > 9 > surprise Percent
31.7308
Earnings History > 10 > period
2023-06-30
Earnings History > 10 > report Date
2023-08-07
Earnings History > 10 > date
2023-06-30
Earnings History > 10 > before After Market
AfterMarket
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
-1.25
Earnings History > 10 > eps Estimate
-0.79
Earnings History > 10 > eps Difference
-0.46
Earnings History > 10 > surprise Percent
-58.2278
Earnings History > 11 > period
2023-03-31
Earnings History > 11 > report Date
2023-05-09
Earnings History > 11 > date
2023-03-31
Earnings History > 11 > before After Market
AfterMarket
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
-0.51
Earnings History > 11 > eps Estimate
-0.95
Earnings History > 11 > eps Difference
0.44
Earnings History > 11 > surprise Percent
46.3158
Earnings History > 12 > period
2022-12-31
Earnings History > 12 > report Date
2023-03-01
Earnings History > 12 > date
2022-12-31
Earnings History > 12 > before After Market
AfterMarket
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
-0.65
Earnings History > 12 > eps Estimate
-1.11
Earnings History > 12 > eps Difference
0.46
Earnings History > 12 > surprise Percent
41.4414
Earnings History > 13 > period
2022-09-30
Earnings History > 13 > report Date
2022-11-09
Earnings History > 13 > date
2022-09-30
Earnings History > 13 > before After Market
AfterMarket
Earnings History > 13 > currency
USD
Earnings History > 13 > eps Actual
-1.68
Earnings History > 13 > eps Estimate
-1.25
Earnings History > 13 > eps Difference
-0.43
Earnings History > 13 > surprise Percent
-34.4
Earnings History > 14 > period
2022-06-30
Earnings History > 14 > report Date
2022-08-09
Earnings History > 14 > date
2022-06-30
Earnings History > 14 > before After Market
AfterMarket
Earnings History > 14 > currency
USD
Earnings History > 14 > eps Actual
-1.44
Earnings History > 14 > eps Estimate
-1.08
Earnings History > 14 > eps Difference
-0.36
Earnings History > 14 > surprise Percent
-33.3333
Earnings History > 15 > period
2022-03-31
Earnings History > 15 > report Date
2022-05-10
Earnings History > 15 > date
2022-03-31
Earnings History > 15 > before After Market
AfterMarket
Earnings History > 15 > currency
USD
Earnings History > 15 > eps Actual
-0.9
Earnings History > 15 > eps Estimate
-1.2
Earnings History > 15 > eps Difference
0.3
Earnings History > 15 > surprise Percent
25
Earnings History > 16 > period
2021-12-31
Earnings History > 16 > report Date
2022-03-01
Earnings History > 16 > date
2021-12-31
Earnings History > 16 > before After Market
AfterMarket
Earnings History > 16 > currency
USD
Earnings History > 16 > eps Actual
-2.17
Earnings History > 16 > eps Estimate
-1.33
Earnings History > 16 > eps Difference
-0.84
Earnings History > 16 > surprise Percent
-63.1579
Earnings History > 17 > period
2021-09-30
Earnings History > 17 > report Date
2021-11-09
Earnings History > 17 > date
2021-09-30
Earnings History > 17 > before After Market
AfterMarket
Earnings History > 17 > currency
USD
Earnings History > 17 > eps Actual
-1.01
Earnings History > 17 > eps Estimate
-1.18
Earnings History > 17 > eps Difference
0.17
Earnings History > 17 > surprise Percent
14.4068
Earnings History > 18 > period
2021-06-30
Earnings History > 18 > report Date
2021-08-09
Earnings History > 18 > date
2021-06-30
Earnings History > 18 > before After Market
AfterMarket
Earnings History > 18 > currency
USD
Earnings History > 18 > eps Actual
-1.76
Earnings History > 18 > eps Estimate
-1.3
Earnings History > 18 > eps Difference
-0.46
Earnings History > 18 > surprise Percent
-35.3846
Earnings History > 19 > period
2021-03-31
Earnings History > 19 > report Date
2021-05-10
Earnings History > 19 > date
2021-03-31
Earnings History > 19 > before After Market
BeforeMarket
Earnings History > 19 > currency
USD
Earnings History > 19 > eps Actual
-2.64
Earnings History > 19 > eps Estimate
-1.58
Earnings History > 19 > eps Difference
-1.06
Earnings History > 19 > surprise Percent
-67.0886
Earnings History > 20 > period
2020-12-31
Earnings History > 20 > report Date
2021-03-01
Earnings History > 20 > date
2020-12-31
Earnings History > 20 > before After Market
BeforeMarket
Earnings History > 20 > currency
USD
Earnings History > 20 > eps Actual
-0.3982
Earnings History > 20 > eps Estimate
-0.99
Earnings History > 20 > eps Difference
0.5918
Earnings History > 20 > surprise Percent
59.7778
Earnings History > 21 > period
2020-09-30
Earnings History > 21 > report Date
2020-12-02
Earnings History > 21 > date
2020-09-30
Earnings History > 21 > before After Market
-
Earnings History > 21 > currency
USD
Earnings History > 21 > eps Actual
-0.3982
Earnings History > 21 > eps Estimate
-0.4
Earnings History > 21 > eps Difference
0.0018
Earnings History > 21 > surprise Percent
0.45
Earnings History > 22 > period
2020-06-30
Earnings History > 22 > report Date
2020-08-13
Earnings History > 22 > date
2020-06-30
Earnings History > 22 > before After Market
BeforeMarket
Earnings History > 22 > currency
USD
Earnings History > 22 > eps Actual
-0.9899
Earnings History > 22 > eps Estimate
-0.99
Earnings History > 22 > eps Difference
0.0001
Earnings History > 22 > surprise Percent
0.0101
Earnings History > 23 > period
2020-03-31
Earnings History > 23 > report Date
2020-06-03
Earnings History > 23 > date
2020-03-31
Earnings History > 23 > before After Market
-
Earnings History > 23 > currency
USD
Earnings History > 23 > eps Actual
-0.9899
Earnings History > 23 > eps Estimate
-0.99
Earnings History > 23 > eps Difference
0.0001
Earnings History > 23 > surprise Percent
0.0101
Earnings History > 24 > period
2019-12-31
Earnings History > 24 > report Date
2020-03-19
Earnings History > 24 > date
2019-12-31
Earnings History > 24 > before After Market
BeforeMarket
Earnings History > 24 > currency
USD
Earnings History > 24 > eps Actual
-0.68
Earnings History > 24 > eps Estimate
-0.59
Earnings History > 24 > eps Difference
-0.09
Earnings History > 24 > surprise Percent
-15.2542
Earnings History > 25 > period
2019-09-30
Earnings History > 25 > report Date
2019-11-27
Earnings History > 25 > date
2019-09-30
Earnings History > 25 > before After Market
-
Earnings History > 25 > currency
USD
Earnings History > 25 > eps Actual
-0.5953
Earnings History > 25 > eps Estimate
-0.6
Earnings History > 25 > eps Difference
0.0047
Earnings History > 25 > surprise Percent
0.7833
Earnings History > 26 > period
2019-06-30
Earnings History > 26 > report Date
2019-09-03
Earnings History > 26 > date
2019-06-30
Earnings History > 26 > before After Market
AfterMarket
Earnings History > 26 > currency
USD
Earnings History > 26 > eps Actual
-0.6717
Earnings History > 26 > eps Estimate
-0.67
Earnings History > 26 > eps Difference
-0.0017
Earnings History > 26 > surprise Percent
-0.2537
Earnings History > 27 > period
2019-03-31
Earnings History > 27 > report Date
2019-05-29
Earnings History > 27 > date
2019-03-31
Earnings History > 27 > before After Market
-
Earnings History > 27 > currency
USD
Earnings History > 27 > eps Actual
-0.6717
Earnings History > 27 > eps Estimate
-0.44
Earnings History > 27 > eps Difference
-0.2317
Earnings History > 27 > surprise Percent
-52.6591
Earnings History > 28 > period
2018-12-31
Earnings History > 28 > report Date
2019-03-07
Earnings History > 28 > date
2018-12-31
Earnings History > 28 > before After Market
BeforeMarket
Earnings History > 28 > currency
USD
Earnings History > 28 > eps Actual
-2.32
Earnings History > 28 > eps Estimate
-0.45
Earnings History > 28 > eps Difference
-1.87
Earnings History > 28 > surprise Percent
-415.5556
Earnings History > 29 > period
2018-09-30
Earnings History > 29 > report Date
2018-11-28
Earnings History > 29 > date
2018-09-30
Earnings History > 29 > before After Market
-
Earnings History > 29 > currency
USD
Earnings History > 29 > eps Actual
-0.33
Earnings History > 29 > eps Estimate
-0.4
Earnings History > 29 > eps Difference
0.07
Earnings History > 29 > surprise Percent
17.5
Earnings History > 30 > period
2018-06-30
Earnings History > 30 > report Date
2018-08-30
Earnings History > 30 > date
2018-06-30
Earnings History > 30 > before After Market
BeforeMarket
Earnings History > 30 > currency
USD
Earnings History > 30 > eps Actual
-0.83
Earnings History > 30 > eps Estimate
-0.26
Earnings History > 30 > eps Difference
-0.57
Earnings History > 30 > surprise Percent
-219.2308
Earnings History > 31 > period
2018-03-31
Earnings History > 31 > report Date
2018-05-02
Earnings History > 31 > date
2018-03-31
Earnings History > 31 > before After Market
BeforeMarket
Earnings History > 31 > currency
USD
Earnings History > 31 > eps Actual
-0.29
Earnings History > 31 > eps Estimate
-0.18
Earnings History > 31 > eps Difference
-0.11
Earnings History > 31 > surprise Percent
-61.1111
Earnings History > 32 > period
2017-09-30
Earnings History > 32 > report Date
2017-11-15
Earnings History > 32 > date
2017-09-30
Earnings History > 32 > before After Market
AfterMarket
Earnings History > 32 > currency
USD
Earnings History > 32 > eps Actual
-0.21
Earnings History > 32 > eps Estimate
-0.23
Earnings History > 32 > eps Difference
0.02
Earnings History > 32 > surprise Percent
8.6957
Earnings History > 33 > period
2017-06-30
Earnings History > 33 > report Date
2017-09-21
Earnings History > 33 > date
2017-06-30
Earnings History > 33 > before After Market
AfterMarket
Earnings History > 33 > currency
USD
Earnings History > 33 > eps Actual
-0.745
Earnings History > 33 > eps Estimate
-
Earnings History > 33 > eps Difference
0
Earnings History > 33 > surprise Percent
-
Earnings History > 34 > period
2016-12-31
Earnings History > 34 > report Date
2017-02-03
Earnings History > 34 > date
2016-12-31
Earnings History > 34 > before After Market
-
Earnings History > 34 > currency
USD
Earnings History > 34 > eps Actual
-0.76
Earnings History > 34 > eps Estimate
0
Earnings History > 34 > eps Difference
-0.76
Earnings History > 34 > surprise Percent
-
Earnings History > 35 > period
2016-06-30
Earnings History > 35 > report Date
2016-08-04
Earnings History > 35 > date
2016-06-30
Earnings History > 35 > before After Market
-
Earnings History > 35 > currency
USD
Earnings History > 35 > eps Actual
-0.24
Earnings History > 35 > eps Estimate
0
Earnings History > 35 > eps Difference
-0.24
Earnings History > 35 > surprise Percent
-
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AHow Investors Are Reacting To Zai Lab (ZLAB) Advancing ZL-1503 And Securing Key NRDL Renewals simplywall.st
Read more →Zai Lab stock hits 52-week low at $18.77 By Investing.com Investing.com UK
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$49.4882
Analyst Picks
Strong Buy
7
Buy
4
Hold
1
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 52.92% of the total shares of Zai Lab Ltd
1.
FMR Inc(5.5697%)
since
2025/06/30
2.
Capital World Investors(5.4248%)
since
2025/06/30
3.
RTW INVESTMENTS, LLC(4.976%)
since
2025/06/30
4.
ClearBridge Advisors, LLC(3.6056%)
since
2025/06/30
5.
Capital Group New Geography Equity Comp(2.9425%)
since
2025/06/30
6.
American Funds New World A(2.9425%)
since
2025/06/30
7.
HHG PLC(1.9752%)
since
2025/06/30
8.
American Funds SMALLCAP World A(1.872%)
since
2025/06/30
9.
ClearBridge International Growth EAFE(1.8112%)
since
2025/07/31
10.
ClearBridge International Growth C(1.8112%)
since
2025/07/31
11.
Fidelity Contrafund(1.4906%)
since
2025/07/31
12.
BAMCO Inc(1.427%)
since
2025/06/30
13.
Wellington Management Company LLP(1.2375%)
since
2025/06/30
14.
Baron Emerging Markets Strategy(1.2184%)
since
2025/06/30
15.
Baron Emerging Markets Institutional(1.2184%)
since
2025/06/30
16.
Woodline Partners LP(1.0794%)
since
2025/06/30
17.
Allianz Asset Management AG(0.8376%)
since
2025/06/30
18.
Rock Springs Capital Management LP(0.7831%)
since
2025/06/30
19.
ADAR1 Capital Management LLC(0.7643%)
since
2025/06/30
20.
MPM Oncology Impact Management LP(0.6696%)
since
2025/06/30
21.
Allianz Oriental Income P USD(0.6375%)
since
2025/07/31
22.
Principal International All Country Eq(0.5814%)
since
2024/12/31
23.
Fidelity Contrafund Commingled Pl S(0.5662%)
since
2025/07/31
24.
T. Rowe Price Health Sciences(0.5594%)
since
2025/07/31
25.
Janus Henderson Global Life Sciences D(0.5486%)
since
2025/06/30
26.
Janus Henderson Global Life Sciences(0.5486%)
since
2025/06/30
27.
Jennison Associates LLC(0.5323%)
since
2025/06/30
28.
Strategic Advisers Fidelity Em Mkts(0.5013%)
since
2025/07/31
29.
Fidelity Series Emerging Markets(0.498%)
since
2025/07/31
30.
CAM Group Holding A/S(0.4583%)
since
2025/06/30
31.
C WorldWide Healthcare Select 1A(0.4583%)
since
2025/07/31
32.
Janus Global Life Science AUSD(0.456%)
since
2025/06/30
33.
Janus Henderson Glb Life Scn I2 USD(0.4454%)
since
2025/07/31
34.
Fidelity Growth Compy Commingled Pl S(0.4406%)
since
2025/07/31
35.
BlackRock Inc(0.4092%)
since
2025/06/30
36.
B Group, Inc(0.3595%)
since
2025/06/30
37.
Connor Clark & Lunn Inv Mgmt Ltd(0.3481%)
since
2025/06/30
38.
Citadel Advisors Llc(0.3291%)
since
2025/06/30
39.
XY Capital Ltd(0.3259%)
since
2025/06/30
40.
Morgan Stanley - Brokerage Accounts(0.2598%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-0.0882
Date
2025-09-30
EPS Actual
-0.33
EPS Estimate
-0.2453
EPS Difference
-0.0847
Surprise Percent
-34.5291%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.